| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WALTHAM, Mass.—Thermo Fisher Scientific Inc. has announced a collaborative training program with Thomas Jefferson University (TJU), the Institute Pasteur and the Organization of International Visitors of the USA (OIV-USA) to preemptively confront the potential threat of an Ebola virus epidemic in Ivory Coast. The partnership will include the training of a visiting scientist, who will learn to screen samples for Ebola using advanced qPCR instruments so they can return to West Africa to train others in the field. The training program will run over the course of four weeks in the lab of Dr. Matthias Schnell, professor of microbiology and immunology at TJU. The collaboration will also provide StepOnePlus Real-Time PCR molecular screening instruments at TJU and in West Africa, where a training center will be established in Abidjan, Ivory Coast.
 
“It is important to provide the countries of West Africa with the proper resources and training to help them combat this outbreak,” said Schnell. “With the generous support of R&D leaders Junko Stevens, Ph.D., and Jonathan Wang, Ph.D., from Thermo Fisher, we have been able to move quickly to get the appropriate state-of-the-art equipment for the training center.”
 
“Preventative steps like those being taken through this collaborative training program are critical to eventually put an end to this epidemic,” said Dan Didier, Head of Public Health, Thermo Fisher Scientific. “As we’ve seen with past outbreaks, this flexible molecular technology can play a key role in identifying and screening samples for many other pathogens affecting human health in the West African region.”
 
The company followed up that news with an announcement of the acquisition of Millersburg, Pa.-based Advanced Scientifics Inc. (ASI), a global provider of single-use technologies for customized bioprocessing solutions. Thermo Fisher Scientific will acquire ASI for $300 million in cash, and the company will be integrated into Thermo Fisher’s Life Sciences Solutions Segment. Accretion to Thermo Fisher's adjusted earnings per share from the deal are expected to be immaterial. ASI saw roughly $80 million in revenues in 2014.
 
“ASI’s intense customer focus has led to the development of innovative solutions that complement our existing single-use technologies and expand our offering across the bioprocessing workflow,” Marc N. Casper, president and CEO of Thermo Fisher Scientific, said in a press release. “We see this acquisition as a great opportunity to meet customer demand for quality and productivity in bioprocessing, and plan to leverage our global reach to bring these innovative products to a larger customer base.”
 
 
SOURCE: Thermo Fisher Scientific press release

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue